tbuckley/cabot-search huggingface dataset:
AB1257 EVALUATION OF ADHERENCE TO AND AGREEMENT WITH THE 2020 AMERICAN COLLEGE OF RHEUMATOLOGY GUIDELINE FOR THE MANAGEMENT OF GOUT BY US RHEUMATOLOGISTS
Authors: N. Schlesinger, M. Pillinger, P. Lipsky
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In 2020, the American College of Rheumatology (ACR) presented an updated gout treatment guideline.<sup>[1]</sup> <h3>Objectives</h3> In this report, we evaluated US rheumatologists' stated adherence to and agreement with the 2020 ACR Guideline for the Management of Gout. <h3>Methods</h3> A 57-item questionnaire was administered to US rheumatologists, surveying their adherence to and agreement with the 2020 ACR Guideline for the Management of Gout. Stated adherence scores were based on the number of Guideline recommendations reported to be followed by rheumatologists in practice, whereas stated agreement scores were based on degree of agreement with the recommendations. <h3>Results</h3> All 201 rheumatologists approached completed the questionnaire. Mean age of participants was 50 years, 54% had &gt;15 years of practice experience, and ~70% were in private practice (<b>Table 1</b>). Mean overall stated adherence score was 11.5, with a possible maximum of 15, whereas the mean overall stated agreement score was 7.7, with a possible maximum of 14. Rheumatologists with less experience (≤8years; n=49) were likely to claim adherence with more individual ACR recommendations than those with more experience (&gt;8years; n=152) (mean stated adherence score: 12.3 vs 11.3; p&lt;0.05), whereas those who claimed to see ≤75 patients with gout in 6 months (n=66) had a mean stated adherence score of 12.1 vs 11.2 for rheumatologists who claimed to have seen &gt;75 patients (p&lt;0.05). Approximately 78% of rheumatologists claimed to follow the guideline for initiating urate lowering therapy (ULT) and 89% were likely to prescribe allopurinol as a first line ULT for all patient types (<b>Figure 1</b>). Claimed adherence to recommendations for dosing was lower (43% and 39%, for febuxostat and allopurinol, respectively). Approximately, 92% of the rheumatologists claimed adherence on first-line therapy for gout flares (<b>Figure 1</b>). Rheumatologists from academic settings were more likely to prescribe an interleukin-1 inhibitor for gout flares than those in other settings. <h3>Conclusion</h3> The self-reported practice of the surveyed US rheumatologists was generally concordant with the 2020 ACR Guideline for the Management of Gout. However, there were gaps in guideline knowledge and stated adherence among rheumatologists, mainly concerning the dosing of treatment regimens. <h3>Reference</h3> [1]Fitzgerald JD, et al. <i>Arthritis Care Res (Hoboken).</i> 2020;72(6):744-760. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Naomi Schlesinger Consultant of: Horizon Pharma, Novartis, JW Pharma, LG chem, Sobi, ANI and Protalix, Grant/research support from: Olatec, Michael Pillinger Consultant of: Horizon Therapeutics, Sobi, Fortress Bioscience, Grant/research support from: Horizon Therapeutics, Hikma Pharmaceuticals, Peter Lipsky Consultant of: Horizon Therapeutics.
Socioeconomic disparities and survival in patients with primary liver cancer by subtype: a french population-based study
Authors: Thi Thu Nga Nguyen, Olivier Dejardin, Jean Baptiste Nousbaum, Anne-Marie Bouvier, Joséphine Gardy, Guy Launoy, Veronique Bouvier, Isabelle Ollivier-Hourmand
Journal: Journal of Hepatology (2023)
AB1252 BONE CHANGES EVALUATION DURING PREGNANCY BY MEANS OF RADIOFREQUENCY ECHOGRAPHIC MULTI SPECTROMETRY (REMS) TECHNOLOGY
Authors: V. A. Degennaro, G. Cagninelli, S. Casciaro, F. Conversano, E. Di Pasquo, F. A. Lombardi, P. Pisani, T. Ghi
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> <b>Degennaro, Cagninelli*, Casciaro*, Conversano*, Di Pasquo*, Lombardi*, Pisani*, Ghi.</b> <b>*Equal contributors in alphabetical order.</b> Typically, pregnancy and lactation greatly expose women to develop osteoporosis due to the high demand of calcium from the foetus or neonate. In some cases, especially in the first pregnancies or in the early breastfeeding period, women with persistent lower back pain, are suspected to be at risk for fragility fractures, mostly involving vertebral fractures<sup>[1]</sup>. Therefore, there is an urgent need to perform an accurate monitoring of the maternal bone health status in order to prevent complications of pregnancy and lactation-associated osteoporosis. <h3>Objectives</h3> Through a longitudinal study, the present work aims to determine the changes of bone status in pregnant women from the first to the third trimester of gestation by means of the non-ionizing Radiofrequency Echographic Multi Spectrometry (REMS) technology. <h3>Methods</h3> A cohort of 43 pregnant women were enrolled in the study. Longitudinal measurement of bone mineral density (BMD) was carried out at the femur during the first (baseline) and third (follow-up) trimesters of pregnancy using the REMS technology. A paired t-test was performed to assess the difference in femoral neck BMD between baseline and follow-up. <h3>Results</h3> Compared to the baseline (first trimester), a significant femoral neck BMD reduction was observed at the follow-up of the third trimester, (0.762 ± 0.075 g/ cm<sup>2</sup><i>versus</i> 0.711 ± 0.074 g/ cm<sup>2</sup>, respectively with p&lt;0.0001). As a result, an overall BMD decrease of 2.07% has be measured. <h3>Conclusion</h3> As previously demonstrated with this technology, pregnant women have a significant decline of BMD compared with the non-pregnant counterpart<sup>[2]</sup>. With this study, for the first time, bone changes throughout pregnancy could be determined by means of this technology: a marked bone reduction was demonstrated in the pregnant group during the last trimester of pregnancy. In conclusion, REMS represents an appropriate method for BMD assessment which can be safely employed to monitor the bone status across gestation and lactation. <h3>References</h3> [1]Qian, Y. et al., BMC Musculoskelet Disord 22, 926 (2021). doi:10.1186/s12891-021-04776-7 [2]Degennaro VA, et al., Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:44-49. doi: 0.1016/j.ejogrb.2021.06.014. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
Authors: Milan Sonneveld, SM Chiu, Jun Yong Park, Sylvia Brakenhoff, A Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Bömmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George Dalekos, Nicole Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy
Journal: Journal of Hepatology (2023)
Yaq-001, a non-absorbable, engineered carbon beads of controlled porosity impacts on gut dysbiosis, gut permeability, organ function and reduces mortality in rodent models of cirrhosis and ACLF
Authors: Jinxia Liu, Jane Macnaughtan, Yi Jin, Frederick Clasen, Francesco De Chiara, Ganesh Ingavle, Paul Cordero, Junpei Soeda, Jude A. Oben, Jia Li, I. Jane Cox, Susan Sandeman, Nathan Davies, Raj Mookerjee, Saeed Shoaie, Rajiv Jalan
Journal: Journal of Hepatology (2023)
Validation and expansion of the American gastroenterological association clinical care pathway for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Authors: Veeral Ajmera, Kaleb Tesfai, Scarlett Lopez, Vanessa Cervantes, Egbert Madamba, Ricki Bettencourt, Lisa Richards, Rohit Loomba
Journal: Journal of Hepatology (2023)
Fully automated approach of machine learning combined with deep learning to forecast the coronary artery disease in patients with non-alcoholic fatty liver disease
Authors: Antonio Cirella, Gaia Sinatti, Angelica Bracci, Laura Evangelista, Pierangela Bruno, Silvano Junior Santini, Gianluigi Greco, Antonella Guzzo, Francesco Calimeri, Ernesto di Cesare, Clara Balsano
Journal: Journal of Hepatology (2023)
Impact of non-selective beta-blockers on first and further hepatic decompensation after transjugular intrahepatic portosystemic shunt insertion
Authors: Anja Tiede, Jim Benjamin Mauz, Lena Stockhoff, Hannah Schneider, Bernhard Meyer, Heiner Wedemeyer, Markus Cornberg, Jan Hinrichs, Tammo Lambert Tergast, Benjamin Maasoumy
Journal: Journal of Hepatology (2023)
Pathophysiological biomarkers associated with resolution of ACLF in patients treated with the liver dialysis device, DIALIVE
Authors: Fausto Andreola, Banwari Agarwal, Rafael Bañares Cañizares, Faouzi Saliba, María Pilar Ballester, Dana Tomescu, Daniel Martin, Vanessa Stadlbauer, Gavin Wright, Mohammed Sheikh, Caroline Morgan, Carlos Alzola, Philip Lavin, Daniel Green, Rahul Kumar, Sophie-Caroline Sacleux, Gernot Schilcher, Sebastian Koball, Andrada Tudor, Jaak Minten, Gema Domenech, Juan Aragones, Karl Oettl, Margret Paar, Katja Waterstradt, Stefanie Bode-Boger, Luis Ibañez Samaniego, Amir Gander, Jan Stange, Georg Lamprecht, Moises Sanchez, Raj Mookerjee, Andrew Davenport, Nathan Davies, Marco Pavesi, Agustin Albillos, Jeremy Cordingley, Hartmut Schmidt, Juan Antonio Carbonell-Asins, Vicente Arroyo, Javier Fernandez, Steffen Mitzner, Rajiv Jalan
Journal: Journal of Hepatology (2023)
AB1249 ASSOCIATION OF SERUM URIC ACID LEVEL WITH HAND OSTEOARTHRITIS
Authors: B. Bengana, S. Abdellaoui, A. Boukabous, H. Guerboukha, S. Lefkir
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Asymptomatic hyperuricemia is often considered as a biological anomaly, when the appearance of the gouty disease rather represents the evolution towards an inflammatory disease. In this case, the inflammation is usually due to a response to crystal deposits in the tissues, associated with cartilage damage, as seen in osteoarthritis. Although we know that neglected gout can lead to osteoarthritis, we still don't know if there is a link between hyperuricemia and osteoarthritis. <h3>Objectives</h3> The aim of this study is to assess the link between asymptomatic hyperuricemia (AH) and hand osteoarthritis (HO). <h3>Methods</h3> It's a cross-sectional study included 46 patients (28 in the HO group and 18 in a group without HO) with mean age of 67.23 ± 4.67 years, 32 women for 14 men. We collected demographic, clinical, biological (uricemia) and radiographic data. The association between AH and digital osteoarthritis was assessed by logistic regression. <h3>Results</h3> The mean serum uric acid level in patients with osteoarthritis was higher than that of patients without osteoarthritis (6.71 ± 1.13 mg/dl versus 6.26 ± 1.26 mg/dl, p=0.021). Hyperuricemia was more common in older patients with osteoarthritis than in those without osteoarthritis (45% vs. 23%, p=0.001). After adjusting for age, gender, body mass index and other variables, the association between asymptomatic hyperuricemia and osteoarthritis remained significant with an odds ratio [OR] of 2.28, for a 95% confidence interval [CI] (1.18-4.80), p=0.023. Subgroup analyzes were performed by sex where significant associations between asymptomatic hyperuricemia and osteoarthritis were obtained in women (p=0.027). <h3>Conclusion</h3> AH is a common comorbidity in elderly patients with hand osteoarthritis. A significant link has been found between AH and hand osteoarthritis in elderly subjects, especially females. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1248 LESSONS TO BE LEARNED FROM REAL LIFE DATA FROM 98 GOUT PATIENTS USING A URICOSURIC: BENZBROMARONE
Authors: I. Hotea, M. Janssen, T. Jansen
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Decreased renal urate excretion is the predominant driver of attracting gout, an auto-inflammatory disease secondary to hyperuricemia. Therefore there is an interest in effective urate lowering therapies with a uricosuric mode of action. <h3>Objectives</h3> The objective of this study was to analyses the efficacy and safety of uricosuric treatment i.e., benzbromarone in a real-life clinical setting. <h3>Methods</h3> data from gout patients was collected retrospectively from the digital hospital dossiers. Inclusion criterium was a diagnosis of gout (ICD10 code M10). Demographics, clinical variables and laboratory parameters at baseline and 6 months were collected. Efficacy was measured from reaching a serum urate target at 6 months, and/or increase in Fractional Urate Exctretion (FeUA). <h3>Results</h3> We analyzed data from 98 gout patients with an indication of benzbromarone treatment. Patients were 70 (±12) years of age, and 90% was male. After 6 months of treatment 90 out of 98 patients (91%) reached a sUA level &lt;0.36 mmol/l (6mg/dL); We found that efficacy appeared to be best in low excretor type gout defined as FeUA&lt;4.5%, as their FeUA increased from the initial mean value FeUA 3.2% (SD±1.0%) to reach in 6 months with benzbromarone mean FeUA of 12.1% (SD±6.9%). A considerable percentage (38%) is using benzbromarone on average for 3.8 (SD 3.4) years. 4 patients stopped benzbromarone treatment due to decrease renal function, condition that was already present prior to uricosuric initiation. <h3>Conclusion</h3> Using available benzbromarone in a real-life context proved to be efficient in lowering sUA levels in 6 months. Renal function must be considered before indicating benzbromarone. Determining FeUA in gout patients can further help better characterize the patient profile from whom is this the best treatment option. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT’S POPULATION
Authors: L. Gragnani, M. Visentini, S. Lorini, S. Santini, G. Lauletta, C. Mazzaro, T. Urraro, Q. Luca, F. Cacciapaglia, P. Ruscitti, A. Tavoni, S. Marri, G. Cusano, L. Petraccia, C. Naclerio, E. Treppo, G. Del Frate, I. Di Cola, V. Raimondo, D. Scorpiniti, M. Monti, L. Puccetti, G. Elia, P. Fallahi, S. Basili, S. Scarpato, F. Iannone, M. Casato, A. Antonelli, A. L. Zignego, C. Ferri
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Cryoglobulinemic Vasculitis (CV) is a rare autoimmune systemic disorder with multiple organ involvement. During the current COVID-19 pandemic, the patients with CV can accounted among frail populations because of the presence of multiple organ involvement, chronic steroid treatment, and more frequent old age. <h3>Objectives</h3> The present study aimed to investigate the prevalence and outcome of COVID-19, as well the safety and immunogenicity of COVID-19 vaccines in a wide CV cohort by a multicenter survey. <h3>Methods</h3> Patients with CV were consecutively recruited at 11 Italian referral centers. CV diagnosis, clinico-serological parameters, COVID-19 tests, and vaccination immunogenicity were carried out according to current methods. <h3>Results</h3> Four-hundred-thirty unselected CV patients (130 M; mean age 70±10.96 years) were recruited from February 2020 to October 2021. COVID-19 prevalence was significantly higher in CV patients compared to the Italian general population (11.9% vs 8.0%, p&lt;0.005); furthermore, we observed a higher mortality in CV subjects with COVID-19 compared to those without (5.9% vs 0.5%, p&lt;0.01). An older age (≥60 years) correlated with a worse COVID-19 outcome. Vaccine was administered in 87% of patients, and 50% received a boostering dose. Disease flares/worsening following the vaccination were significantly less frequent than those associated to COVID-19 (5% vs 14%, p=0.0012). CV patients showed an impaired vaccination immunogenicity compared to controls (p&lt;0.05), as well an increased no-response rate after the booster. <h3>Conclusion</h3> CV patients have a higher risk to develop COVID-19, as well of more severe disease manifestations. Vaccines had a good safety profile in CV patients and of note, the vaccine-related side effects/disease flares were significantly lower compared to those COVID-19-related. However, a quarter of vaccinated individuals do not show detectable seroconversion; this is a major challenge for clinicians. Overall, a close monitoring of these frail patients during the ongoing pandemic is particularly advisable. <h3>References</h3> [1]Ferri C, et al. Ann Rheum Dis. 2020 Oct 14 doi: 10.1136/ annrheumdis-2020-219113. [2]Visentini M et al. Ann Rheum Dis. 2021 Nov 24. doi: 10.1136/ annrheumdis-2021-221248 [3]Ferri C et al. J Autoimmun. 2022 Jul;131:102866. doi: 10.1016/j <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Microbiota-targeted interventions in the gut-liver axis for chronic liver disease of DUAL etiology
Authors: Raquel Benedé, Olga Estévez, Hector Leal, Salvador Iborra, Ana Redondo, José María Herranz, Alexander Tyakht, Viktoria Odintsova, Beatriz Gómez Santos, Patricia Aspichueta, Johanna Reißing, Tony Bruns, Andreea Ciudin, Juan M. Pericas, Javier Vaquero, Christian Trautwein, Christian Liedtke, Rafael Bañares, Matías A. Avila, Francisco Javier Cubero, Yulia Nevzorova
Journal: Journal of Hepatology (2023)
Evaluation of the performance of a novel single-nuclei digital pathology method for the continuous quantification of steatosis and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH
Authors: Louis Petitjean, Li Chen, Dmitri Fedorov, Aras Mattis, Mojgan Hosseini, Mathieu Petitjean, Arun Sanyal, Cynthia Behling
Journal: Journal of Hepatology (2023)
Prospective, multi-center, open-label, randomized, omega-3-acid ethyl ester-controlled trial to assess the impact of the pemafibrate on liver function in hypertriglyceridemia patients with non-alcoholic fatty liver disease (Portrait study)
Authors: Yoshio Sumida, Masashi Yoneda, Kiyoaki Itoh, Yukiomi Nakade, Satoshi Kimoto, Kazumasa Sakamoto, Hidenori Toyoda
Journal: Journal of Hepatology (2023)
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
Authors: Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Hidenori Toyoda, Kazuya Kariyama, Takeshi Hatanaka, Satoru Kakizaki, Atsushi Naganuma, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso
Journal: Liver Cancer (2023)

Introduction: Because of recent developments in treatments for hepatocellular carcinoma (HCC), methods for determining suitable therapy for initial or recurrent HCC have become important. This study used artificial intelligence (AI) findings to establish a system for predicting prognosis of HCC patients at time of reoccurrence based on clinical data as a reference for selection of treatment modalities. Methods: As a training cohort, 5,701 observations obtained at the initial and each subsequent treatment for recurrence from 1,985 HCC patients at a single center from 2000 to 2021 were used. The validation cohort included 5,692 observations from patients at multiple centers obtained at the time of the initial treatment. An AI calculating system (PRAID) was constructed based on 25 clinical factors noted at each treatment from the training cohort, and then predictive prognostic values for 1- and 3-year survival in both cohorts were evaluated. Results: After exclusion of patients lacking clinical data regarding albumin-bilirubin (ALBI) grade or tumor-node-metastasis stage of the Liver Cancer Study Group of Japan, 6th edition (TNM-LCSGJ 6th), ALBI-TNM-LCSGJ 6th (ALBI-T) and modified ALBI-T scores confirmed that prognosis for patients in both cohorts was similar. The area under the curve for prediction of both 1- and 3-year survival in the validation cohort was 0.841 (sensitivity 0.933 [95% CI: 0.925–0.940], specificity 0.517 [95% CI: 0.484–0.549]) and 0.796 (sensitivity 0.806 [95% CI: 0.790–0.821], specificity 0.646 [95% CI: 0.624–0.668]), respectively. Conclusion: The present PRAID system might provide useful prognostic information related to short and medium survival for decision-making regarding the best therapeutic modality for both initial and recurrent HCC cases.
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
Authors: Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E Gaillard, Chan Kim, Hong Jae Chon
Journal: Liver Cancer (2023)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological significance of thyroid dysfunction in patients treated with Ate/Bev has not been comprehensively addressed. We aimed to comprehensively evaluate the clinical and immunological implications of thyroid dysfunction in unresectable HCC patients treated with Ate/Bev. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; We enrolled 208 patients with unresectable HCC treated with Ate/Bev from three Korean cancer centers. Thyroid adverse events (AEs) were reviewed, and cytokines and T cells in the blood samples were analyzed at baseline. For external validation, we analyzed clinical outcomes according to thyroid AEs in patients treated with Ate/Bev in the IMbrave150 study. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Forty-one (19.7%) out of 208 patients experienced thyroid dysfunction (hypothyroidism [17.3%] and thyrotoxicosis [5.8%]) after Ate/Bev treatment. Median time to onset of hypothyroidism and thyrotoxicosis after Ate/Bev treatment was 3.5 and 1.3 months, respectively. Patients with thyroid AEs demonstrated significantly better progression-free survival, overall survival, and objective response rate than those without thyroid AEs. These findings were still consistent even after adjusting for confounding factors. Furthermore, favorable survival outcomes in patients with thyroid AEs were also validated in a cohort of IMbrave150 patients. While patients with thyrotoxicosis showed a significantly lower level of baseline IL-6, those with hypothyroidism did not show significant differences in circulating cytokine levels and CD8&lt;sup&gt;+&lt;/sup&gt; T-cell fractions. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; A fraction of patients with HCC treated with Ate/Bev experienced thyroid dysfunction, and the development of thyroid AEs was associated with favorable clinical outcomes.